Who is sponsoring NCT05431218?

NCT05431218 is sponsored by Karaganda Medical University.

What drugs are being tested in NCT05431218?

Interventions in NCT05431218: Cholecalciferol Liquid.

What condition does NCT05431218 study?

NCT05431218 studies Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease Moderate, Chronic Obstructive Pulmonary Disease Severe.

Is NCT05431218 still recruiting?

NCT05431218 is currently completed. Last updated 12 April 2024.

Last reviewed 2024-04-12 · How we verify

NCT05431218: COPD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Association of Cathelicidin and Vitamin D Levels With the Category and Course of COPD

Completed Phase 4 Last updated 12 April 2024

What this trial tests

Phase 4 trial testing Cholecalciferol Liquid in Chronic Obstructive Pulmonary Disease in 120 participants. Completed in 31 December 2021.

Timeline

18 February 2020

Primary endpoint
30 December 2021

31 December 2021

Quick facts

Lead sponsor	Karaganda Medical University
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	120
Start date	18 February 2020
Primary completion	30 December 2021
Estimated completion	31 December 2021
Sites	1 location across Kazakhstan

Drugs / interventions tested

Cholecalciferol Liquid — full drug profile →

Conditions studied

Chronic Obstructive Pulmonary Disease — all drugs for Chronic Obstructive Pulmonary Disease →
Chronic Obstructive Pulmonary Disease Moderate — all drugs for Chronic Obstructive Pulmonary Disease Moderate →
Chronic Obstructive Pulmonary Disease Severe — all drugs for Chronic Obstructive Pulmonary Disease Severe →

Sponsor

Karaganda Medical University

Who can join

Adults 18 to 84, any sex, with Chronic Obstructive Pulmonary Disease or Chronic Obstructive Pulmonary Disease Moderate. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Recruitment of patients with COPD. Assessment of clinical status, determination of vitamin D and cathelicidin levels. In the group with vitamin D deficiency, patients receive cholecalciferol (vitamin D) daily for 3 months. After 3 months, the clinical status was assessed again, the level of vitamin D and cathelicidin was determined. When vitamin D levels normalize, cholecalciferol replacement therapy is discontinued for 3 months. After that, a control inspection and laboratory tests are performed.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Lung antimicrobial proteins and peptides: from host defense to therapeutic strategies.
Di YP, Kuhn JM, Mangoni ML. · · 2024 · cited 22× · PMID 39052018 · DOI 10.1152/physrev.00039.2023
Antimicrobial Peptides: Mechanisms, Applications, and Therapeutic Potential.
Alzain M, Daghistani H, Shamrani T, Almoghrabi Y, et al · · 2025 · cited 8× · PMID 40901006 · DOI 10.2147/idr.s514825

Verify or expand the search:

Other recruiting trials for Chronic Obstructive Pulmonary Disease

Currently open trials in the same condition.

NCT06749262 — Inclined Versus Standard Exercise for COPD Patients · NA · recruiting
NCT07406659 — Different Inspiratory Muscle Trainings in Patients With COPD · NA · recruiting
NCT07051707 — Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD · NA · recruiting
NCT07418736 — A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease · Phase 2 · recruiting
NCT07069829 — Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo · recruiting

Other Karaganda Medical University trials

Trials by the same sponsor.

NCT07294911 — Predictors of Contrast-induced Acute Renal Injury in Patients With Acute Coronary Syndrome · completed
NCT06460753 — Analysis of Laboratory Markers for Severe COVID-19 · completed
NCT06937346 — Rehabilitation Robotic System ReHand · NA · completed
NCT06221293 — Correlation Between Intra-abdominal Pressure, Biomarkers of Bacterial Translocation and Intestinal Wall Damage · active not recruiting
NCT05222893 — Optimization of PEEP During Laparoscopic Surgery · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05431218 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Karaganda Medical University
Last refreshed: 12 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05431218.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing